|
Fig. 7 Dimercaprol increases GSH levels and inhibits spontaneous ‘seizure-like’ swim behavior in DS (scn1Lab) mutants. 5-7 dpf scn1Lab mutants were treated with 10, 30 or 100 μM dimercaprol for 4 h. GSH levels were measured by HPLC. (A) DS mutants' GSH levels. DS mutants were treated with increasing concentrations of DMP for 4 h and swim behavior was assessed by the Noldus DanioVision system running the EthoVisionXT software. 10 μM stiripentol was used as a positive control. (B) Change in larval swim velocity correlated to ‘seizure-like’ behavior. The dotted black line at ∼ −40% represents the cut-off point below which velocity values corresponding to larval swim behavior are considered significantly reduced. Data are represented as mean ± SEM (error bars). *p < 0.05, ***p < 0.001, ****p < 0.0001, ns: not significant versus vehicle control by one-way ANOVA with Dunnett's post-hoc test (A and B). n = 50–70 larvae pooled/grp (HPLC assay) and n = 10 larvae/grp (Noldus assay). N = 4–5 experimental replicates. Mean ± SD of raw data values of GSH normalized to total protein (nmol/mg protein) are stated in parentheses (GSH) for each treatment group: a) Veh ctrl (14.2 ± 2.7); b) 10 μM DMP (15.2 ± 4.4); c) 30 μM DMP (16.3 ± 2.4); and d) 100 μM DMP (19.8 ± 2.0) (7A).